A detailed history of Oppenheimer & CO Inc transactions in Novartis Ag stock. As of the latest transaction made, Oppenheimer & CO Inc holds 30,938 shares of NVS stock, worth $3.29 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
30,938
Previous 30,996 0.19%
Holding current value
$3.29 Million
Previous $3.13 Million 4.38%
% of portfolio
0.05%
Previous 0.06%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$95.27 - $108.47 $5,525 - $6,291
-58 Reduced 0.19%
30,938 $2.99 Million
Q4 2023

Feb 13, 2024

BUY
$92.27 - $101.54 $49,548 - $54,526
537 Added 1.76%
30,996 $3.13 Million
Q3 2023

Nov 07, 2023

BUY
$94.73 - $105.13 $4,262 - $4,730
45 Added 0.15%
30,459 $3.1 Million
Q2 2023

Aug 02, 2023

SELL
$92.52 - $104.91 $59,767 - $67,771
-646 Reduced 2.08%
30,414 $3.07 Million
Q1 2023

May 10, 2023

SELL
$80.03 - $92.81 $39,454 - $45,755
-493 Reduced 1.56%
31,060 $2.86 Million
Q4 2022

Feb 07, 2023

SELL
$75.55 - $92.52 $119,746 - $146,644
-1,585 Reduced 4.78%
31,553 $2.86 Million
Q3 2022

Nov 14, 2022

SELL
$74.61 - $87.26 $114,974 - $134,467
-1,541 Reduced 4.44%
33,138 $2.52 Million
Q2 2022

Aug 08, 2022

SELL
$80.52 - $93.75 $112,164 - $130,593
-1,393 Reduced 3.86%
34,679 $2.93 Million
Q1 2022

May 12, 2022

BUY
$80.11 - $90.62 $660,827 - $747,524
8,249 Added 29.65%
36,072 $3.17 Million
Q4 2021

Feb 02, 2022

BUY
$79.7 - $88.13 $29,568 - $32,696
371 Added 1.35%
27,823 $2.43 Million
Q3 2021

Nov 12, 2021

SELL
$81.78 - $95.14 $396,305 - $461,048
-4,846 Reduced 15.0%
27,452 $2.25 Million
Q2 2021

Aug 03, 2021

SELL
$85.24 - $94.15 $110,130 - $121,641
-1,292 Reduced 3.85%
32,298 $2.95 Million
Q1 2021

May 10, 2021

SELL
$83.5 - $98.47 $443,301 - $522,777
-5,309 Reduced 13.65%
33,590 $2.87 Million
Q4 2020

Feb 11, 2021

SELL
$78.07 - $94.43 $20,610 - $24,929
-264 Reduced 0.67%
38,899 $3.67 Million
Q3 2020

Nov 13, 2020

SELL
$82.14 - $91.0 $80,250 - $88,907
-977 Reduced 2.43%
39,163 $3.41 Million
Q2 2020

Aug 11, 2020

SELL
$80.93 - $91.1 $95,578 - $107,589
-1,181 Reduced 2.86%
40,140 $3.51 Million
Q1 2020

May 08, 2020

SELL
$70.67 - $99.01 $40,493 - $56,732
-573 Reduced 1.37%
41,321 $3.41 Million
Q4 2019

Feb 07, 2020

SELL
$84.35 - $95.37 $263,087 - $297,459
-3,119 Reduced 6.93%
41,894 $3.97 Million
Q3 2019

Oct 31, 2019

BUY
$85.54 - $94.26 $33,959 - $37,421
397 Added 0.89%
45,013 $3.91 Million
Q2 2019

Aug 09, 2019

SELL
$75.4 - $92.8 $21,790 - $26,819
-289 Reduced 0.64%
44,616 $4.07 Million
Q1 2019

Apr 24, 2019

BUY
$75.32 - $86.15 $545,542 - $623,984
7,243 Added 19.23%
44,905 $4.32 Million
Q4 2018

Jan 29, 2019

BUY
$73.66 - $82.02 $73,733 - $82,102
1,001 Added 2.73%
37,662 $3.23 Million
Q3 2018

Oct 26, 2018

SELL
$66.94 - $77.43 $945,594 - $1.09 Million
-14,126 Reduced 27.81%
36,661 $3.16 Million
Q2 2018

Aug 10, 2018

BUY
$64.91 - $73.36 $83,798 - $94,707
1,291 Added 2.61%
50,787 $3.84 Million
Q1 2018

May 01, 2018

BUY
$70.39 - $84.15 $45,753 - $54,697
650 Added 1.33%
49,496 $4 Million
Q4 2017

Feb 07, 2018

BUY
$72.33 - $77.64 $6,292 - $6,754
87 Added 0.18%
48,846 $4.1 Million
Q3 2017

Nov 09, 2017

BUY
$74.14 - $77.27 $3.61 Million - $3.77 Million
48,759
48,759 $4.19 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $229B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.